ArticleEmerging microbes & infections2024
Novel nitroxoline derivative combating resistant bacterial infections through outer membrane disruption and competitive NDM-1 inhibition.
Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Targeting Outer Membrane Vesicles ofJournal of microbiology and biotechnology · 2026Review
- Investigating the therapeutic potential of the antibacterial drug nitroxoline in combating cryptococcal infection.PLoS neglected tropical diseases · 2026Article
- Nitroxoline revisited: antibacterial mechanisms, spectrum, and therapeutic potential of an old drug in the era of antimicrobial resistance.Biochemical Society transactions · 2026Review
- In vitro and in vivo activity of colistin-nitroxoline combination against polymyxin heteroresistant carbapenem-resistant Klebsiella pneumoniae.BMC microbiology · 2026Article
- Nitroxoline exerts potent anti-Antimicrobial agents and chemotherapy · 2026Article
- Antifungal potential of naphthoquinone derivatives: screening of shikonin-based compounds and mechanistic insights into 5,8-dihydroxy-1,4-naphthoquinone againstMicrobiology spectrum · 2026Article
- Uncovering nitroxoline activity spectrum, mode of action and resistance across Gram-negative bacteria.Nature communications · 2025Article
- Docosahexaenoic Acid-Driven Metabolic Reprogramming as an Attractive Anti-Infection Strategy to Potentiate β-Lactam Antibiotic Efficacy.Research (Washington, D.C.) · 2025Article
- Review
- Combination of aloe emodin, emodin, and rhein from Aloe with EDTA sensitizes the resistantFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.